Abstract
Two clinical results of peripheral blood stem cell support are commonly considered: (1) the effect on hematopoietic recovery and (2) the effect on the underlying malignancy. The dynamics of hematopoietic recovery after autoiogous bone marrow transplantation and after autologous peripheral blood stem cell transplantation in a clinical setting are similar if no exogenous cytokines are administered and the peripheral stem ceils are collected while their numbers are not deliberately increased (mobilised). If mobilized peripheral stem cells are transplanted, hematopoietic recovery is accelerated. In some circumstances, patients who receive peripheral stem cell transplantation may experience an improved progression-free survival after high-dose therapy when compared with similar patients who receive autologous bone marrow transplantation. Explanations for such a survival advantage might include (1) a lower likelihood of occult tumor cells capable of restoring disease in peripheral stem cell autograft products than in bone marrow harvests, (2) a greater number of cytotoxic effector cells capable of destroying occult tumor ceils in the peripheral stem cell collections than in bone marrow harvests, and (3) a different and advantageous pattern of immunologic recovery following autologous peripheral stem cell transplant compared to autologous bone marrow transplant.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kessinger A, Vose JM, Bierman PJ, Bishop MR, Armitage JO. Peripheral blood stem cell transplantation in malignant lymphomas.Hem/Onc Ann,2, 47 (1994).
Stadtmauer EA. Peripheral blood stem cell transplantation in breast cancer.Hem/Onc Ann,2, 61 (1994).
Jagannath S, Vesole DH, Barlogie B, Tricot G. Peripheral blood stem cell transplantation in multiple myeloma.Hem/Onc Ann,2, 53 (1994).
Kessinger A. Is blood or bone marrow better?Stem Cells,11, 290 (1993).
To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp DL, Dale BM, Dart GW, Roberts MM, Sage RE, Juttner CA. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood.ExpHematol,18, 442 (1990).
Brugger W, Bross K, Frisch J, Dern P, Weber B, Mertelsmann R, Kanz L. mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following poly-chemotherapy with etoposide, ifosfamide and cisplatin.Blood,79, 1193 (1992).
Bishop MR, Anderson JR, Jackson JD, Bierman PJ, Reed EC, Vose JM, Armitage JO, Warkentin PI, Kessinger A. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft.Blood,83, 610 (1994).
To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp DL, Dale BM, Dart WD, Roberts MM, Sage RE, Juttner CA. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood.Exp Hematol,18, 442 (1990).
Socinski MA, Cannistra AS, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macropbage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man.Lancet,i, 1194 (1988).
Hohaus S, Goldschmidt H, Ehrhardt R, Haas R. Successful autografting following myeloablative conditioning therapy with blood stem cells mobilized by chemotherapy plus rhG-CSF.Exp Hematol,21, 508 (1993).
Schwartzberg L, Birch R, Blanco R, Wittlin F, Muscato J, Tauer K, Hazelton B, West W. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion alone following high-dose therapy.Bone Marrow Transplant,11, 369 (1993).
Kessinger A, Vose JiM, Bierman PJ, Armitage JO. High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone marrow purging.Exp Hematol,19, 1013 (1991).
Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC, Gordon B, Armitage JO. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for aggressive non-Hodgkin’s lymphoma.J Clin Oncol,11, 1846 (1993).
Sharp JG, Vaughan WP, Kessinger A, Mann SL, DeBoer JM, Sanger WG, Weisenburger DD. Significance of detection of tumor cells in hematopoietic stem cell harvests of patients with breast cancer, in Dicke KA, Armitage JO, Dicke-Evinger MJ (eds):Proceedings of the Fifth International Symposium for Autologous Bone Marrow Transplantation, pp.385–391, Omaha, University of Nebraska Medical Center (1991).
Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors.Blood,83, 636, (1994)
Verbik DJ, Jackson JD, Pirmccello SJ, Patil KD, Kessinger A, Joshi SS. Characterisation of GM-CSF mobilized human peripheral stem cell harvests obtained from consecutive collections.Blood,82, 654a, (1993).
Verbik DJ, Jackson JD, Pirruccello S J, Kessinger A, Joshi SS. Augmentation of cytotoxicity of peripheral blood stem cells after in vitro activation with cytokines.Blood,80, 433a, (1992).
Porter DL, Roth MS, McGarigle C, Ferrara JLM, Antin JH: Induction ofgraft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.N Eng J Med,330, 100, (1994).
Gordy C, Perry G, Thomas M, Reed E, Arneson M, Talmadge JE. Immune function and phenotype of peripheral blood and bone marrow stem cell products and peripheral blood reconstitution.J Cell Biochem,18B, 100, (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kessinger, A., Armitage, J., Bierman, P. et al. Clinical outcome of peripheral blood stem cell support. Med Oncol 11, 43–46 (1994). https://doi.org/10.1007/BF02988829
Issue Date:
DOI: https://doi.org/10.1007/BF02988829